Pendal Group’s Pacific Biosciences PACB Stock Holding History

Pendal Group’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-132,147	Closed	-$955K	–	463
2019 Q1	$955K	Hold	132,147	–	–	0.01%	301
2018 Q4	$978K	Buy	+132,147	New	+$837K	0.02%	270

Other funds holding PACB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Versor Investments New York $47.5M AUM 100.43% 1-Year Est. Return

WIC

Water Island Capital New York $1.08B AUM 105.75% 1-Year Est. Return

Pendal Group's PACB Position: Q2 2019 in Review

Pendal Group sold out of Pacific Biosciences (PACB) in Q2 2019, closing a stake of 132,147 shares — an estimated $955K sold.

Pendal Group first reported a position in PACB in Q4 2018 and held it in 2 quarters. The position peaked at $978K in Q4 2018. 150 funds tracked by Wall St. Rank hold PACB as of Q2 2019.

Pendal Group reported no remaining Pacific Biosciences position as of Q2 2019 after selling out during the quarter.
Pendal Group sold 132,147 Pacific Biosciences shares in Q2 2019, an estimated $955K.
Pendal Group first reported a position in Pacific Biosciences in Q4 2018 and held it in 2 quarters.
Pendal Group's Pacific Biosciences position peaked at $978K in Q4 2018.
150 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2019.

Based on Pendal Group's 13F filing for Q2 2019, filed 1 Aug 2019.